Collectively, these studies indicate Notch4 upregulation among the mechanisms promoting the resistance to the hormonal therapy in ER+ breast tumors and suggest its targeting as a potential strategy to overcome the relapsed disease. This evidence concerns the gene NOTCH4 and breast neoplasm.